Selecxine Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 18

Selecxine General Information

Description

Developer of anti-cancer immunotherapeutics drugs intended to provide safe and efficient therapeutics for cancer patients. The company's drugs regulate the function of cytokines that play a key role in the activation of immune cells, enabling doctors to improve the survival rate and quality of life of cancer patients.

Contact Information

Website
www.selecxine.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Bio Open Innovation Center
  • Suite 1204, 47, Jigok-ro, Nam-gu, Pohang-si
  • Pohang, Gyeongsangbuk 790-834
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
LOHAS & Wellness, Life Sciences, Oncology
Corporate Office
  • Bio Open Innovation Center
  • Suite 1204, 47, Jigok-ro, Nam-gu, Pohang-si
  • Pohang, Gyeongsangbuk 790-834
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Selecxine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 15-Jul-2024 Completed Startup
3. Early Stage VC (Series B) 29-Mar-2022 Completed Startup
2. Early Stage VC (Series A) 05-Jul-2020 $20M $22.8M Completed Pre-Clinical Trials
1. Seed Round 01-Jan-2019 $2.76M $2.76M Completed Pre-Clinical Trials
To view Selecxine’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Selecxine Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Selecxine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026082989-A Antibodies specifically binding to human dr3 and use thereof Pending 17-Jun-2022
JP-7849919-B2 Antibodies that specifically bind to human dr3 and their applications Active 17-Jun-2022
EP-4501966-A1 Antibody specifically binding to human dr3 and use thereof Pending 17-Jun-2022
EP-4501966-A4 Antibody specifically binding to human dr3 and use thereof Pending 17-Jun-2022
EP-4810512-A2 Antibody specifically binding to human dr3 and use thereof Pending 17-Jun-2022 C07K16/2878
To view Selecxine’s complete patent history, request access »

Selecxine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Selecxine Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
BM Ventures Venture Capital Minority
Hyundai Technology Investment Venture Capital Minority
Hyundai Venture Investment Corporation Venture Capital Minority
iM Investment Partners Corporate Venture Capital Minority
K-Clavis Asset Manager Minority
You’re viewing 5 of 18 investors. Get the full list »

Ready to get started?

Request a free trial

Selecxine FAQs

  • When was Selecxine founded?

    Selecxine was founded in 2018.

  • Where is Selecxine headquartered?

    Selecxine is headquartered in Pohang, South Korea.

  • What is the size of Selecxine?

    Selecxine has 18 total employees.

  • What industry is Selecxine in?

    Selecxine’s primary industry is Drug Discovery.

  • Is Selecxine a private or public company?

    Selecxine is a Private company.

  • What is Selecxine’s current revenue?

    The current revenue for Selecxine is .

  • How much funding has Selecxine raised over time?

    Selecxine has raised $49.8M.

  • Who are Selecxine’s investors?

    BM Ventures, Hyundai Technology Investment, Hyundai Venture Investment Corporation, iM Investment Partners, and K-Clavis are 5 of 18 investors who have invested in Selecxine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process